Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02822937 · ClinicalTrials.gov registry record · NA
Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents
A NA study, sponsored by Akili Interactive Labs.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT02822937: Completed NA study, sponsored by Akili Interactive Labs.
NCT02822937 is a NA study that has completed, run by Akili Interactive Labs. The registered enrollment target is 18 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02822937, a NA study, has completed, sponsored by Akili Interactive Labs.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a study in adults to assess the sensitivity of Project: EVO Monitor cognitive measurements to two short-acting cognitively active pharmacological agents. The participants will receive a placebo, and two pharmacological agents in a randomized order for three in-clinic study days. During each study day in the clinic, the participants will use Project: EVO Monitor and another cognitive task through the day.
Interventions
- DRUG Placebo
- DRUG Methylphenidate
- DRUG Triazolam
- OTHER Project: EVO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-07 |
| Est. Completion | 2016-11 |
| Phase | NA |
What the finished NCT02822937 record still lists
NCT02822937 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02822937 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02822937 about?
NCT02822937 is a clinical study titled "Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents". This is a study in adults to assess the sensitivity of Project: EVO Monitor cognitive measurements to two short-acting cognitively active pharmacological agents. The participants will receive a placebo, and two pharmacological agents in a randomized order for three in-clinic study days. During each ...
What is the current status of trial NCT02822937?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2016-07. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02822937?
The interventions under investigation include: Placebo (DRUG), Methylphenidate (DRUG), Triazolam (DRUG), Project: EVO (OTHER).
Who is sponsoring clinical trial NCT02822937?
This trial is sponsored by Akili Interactive Labs, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02822937's enrollment target sits among peer trials
18 1863rd of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia